Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
Authors:
- I. N. OlverIOI. N. Olver
- P. GrimisonPGP. Grimison
- M. ChatfieldMCM. Chatfield
- M. R. StocklerMSM. R. Stockler
- G. C. TonerGTG. C. Toner
- V. GebskiVGV. Gebski
- R. HarrupRHR. Harrup
- C. UnderhillCUC. Underhill
- G. KichenadasseGKG. Kichenadasse
- N. SinghalNSN. Singhal
- I. D. DavisIDI. D. Davis
- A. BolandABA. Boland
- 30 December 2012
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 21 (6) , 1561-1568
Abstract
The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy.Keywords
This publication has 18 references indexed in Scilit:
- Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group studySupportive Care in Cancer, 2011
- Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized TrialJNCI: Journal of the National Cancer Institute, 2010
- Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statementSupportive Care in Cancer, 2010
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnnals of Oncology, 2010
- Understanding the concept of chemotherapy-related nausea: the patient experienceEuropean Journal of Cancer Care, 2008
- Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancerSupportive Care in Cancer, 2007
- Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyCancer, 2005
- Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapySupportive Care in Cancer, 2004
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomitingCancer, 2003
- Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferretsNeuropharmacology, 1996